The FDA has launched a PreCheck Pilot Program to accelerate reviews of new manufacturing facilities, selecting seven companies including Eli Lilly and Regeneron as the first participants.
Impact: The program could shorten time‑to‑market for new drug production, boosting earnings potential for the selected firms.
Not investment advice